Oxidative Damage and Antioxidative Therapy in Systemic Sclerosis
Bogna Grygiel‐Górniak, Mariusz Puszczewicz · Mediators of Inflammation · 2014
Systemic sclerosis (SSc) is an autoimmune connective tissue disorder of unknown etiology. This disease is characterized by a large variety of clinical patterns, which include the fibrosis of skin and visceral organs causing a variety of clinical manifestations. Genetic and environmental factors participate in the etiology of this disease; however, recently many studies underline the oxidative background influencing the course and complications of this disease. Reactive oxygen species (ROS) synthesized in SSc can mediate extra- and intracellular oxidative processes affecting endothelial cells and fibroblasts. The estimation of prooxidative markers in the pathogenesis of SSc can enable the identification of useful markers for disease activity and, thus, may help in planning appropriate therapy focusing on the fibrotic or vascular pattern. Recently, many attempts have been made to find antioxidative molecules (nutritional and pharmacological) reducing the prooxidant state in a variety of cells--mainly in endothelium and proliferating fibroblasts. This paper presents both the background of oxidative stress processes in systemic sclerosis mediated by different mechanisms and the evidence suggesting which of the dietary and pharmacological antioxidants can be used as therapeutic targets for this disease.
Cited by 58 works. doi:10.1155/2014/389582 Open-access PDF
Authors
References
- Advanced oxidation protein products as a novel marker of oxidative stress in uremia
- High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
- Antioxidant defense systems: the role of carotenoids, tocopherols, and thiols
- Severe organ involvement in systemic sclerosis with diffuse scleroderma
- Scleroderma
- Systemic sclerosis: a prototypic multisystem fibrotic disorder
- Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation by silica in inflammation and fibrosis
- Stimulatory Autoantibodies to the PDGF Receptor in Systemic Sclerosis
- Controlling Tumor Growth by Modulating Endogenous Production of Reactive Oxygen Species
- Pathogenesis of Raynaud's phenomenon